Top Transcatheter Embolization and Occlusion Devices Companies

Transcatheter Embolization and Occlusion Devices Market size was valued at USD 4.82 Billion in 2023 and is poised to grow from USD 5.17 Billion in 2024 to USD 9.02 Billion by 2032, growing at a CAGR of 7.20% during the forecast period (2025-2032).

The competitive landscape of the transcatheter embolization and occlusion devices industry is characterized by numerous global and regional players investing in new products, strategies and geographical expansion to force them to build their market position strength. Key players focus on developing advanced embolic drugs, improving application, expanding their product lines to address various medical conditions. For example, partnerships between device manufacturing and clinical or research between institutions to stimulate clinical certification, product development and approval processes are common.   'Boston Scientific Corporation (US) ', 'Terumo Corporation (Japan) ', 'Medtronic (Ireland) ', 'Abbott (US)  ', 'Cook Medical Inc. (US) ', 'Penumbra, Inc. (US) ', 'Cerenovus (a subsidiary of Johnson & Johnson) (US) ', 'Guerbet S.A. (France) ', 'Merit Medical Systems, Inc. (US) ', 'AngioDynamics, Inc. (US) ', 'B. Braun Melsungen AG (Germany) ', 'Humares (Germany) ', 'Inari Medical, Inc. (US) ', 'MicroVention, Inc. (US) ', 'Endospan Ltd. (Israel) ', 'Teleflex Incorporated (US) ', 'Kaneka Corporation (Japan) ', 'Abbott Vascular (a division of Abbott Laboratories) (US) ', 'SentreHEART, Inc. (US) ', 'Vascular Technologies (US)'

The increasing burden of chronic diseases such as cancer, liver disease and cardiovascular diseases is driving demand for less invasive medical solutions such as transcatheter embolization occlusion (TEO) devices. It is one of the leading causes of cancer death worldwide, especially for refractory tumors. Embolization techniques are emerging as an effective palliative treatment. This has led to the adoption of TEO devices by healthcare facilities to improve patient outcomes, contributing significantly to the transcatheter embolization and occlusion devices market growth. 

Increasing Preference for Nonsurgical Treatment: Patients and health care providers are increasingly preferring minimally invasive surgery over conventional surgery due to decreased complications, shorter recovery times, and lower risks. Changing preferences has led to a demand for implantable devices as an alternative to open surgery. The trend is consistent with the global focus on patient-centered care, further increasing the use of TEO devices. 

As per transcatheter embolization and occlusion devices market outlook, North America led the market with 29.7% revenue share in 2022. Availability of advanced healthcare infrastructure, well-defined regulatory framework, and skilled healthcare professionals are the major drivers for TEO demand devices in this region. According to the Centers for Disease Control and Prevention (CDC), these devices are used in cases of migraine and muscle spasms; Each year, 454,000 people are diagnosed with atrial fibrillation. The market is characterized by a few major players, including Abbott Laboratories, Boston Scientific Corporation, and Medtronic PLC, who are continuously innovating and expanding their product offerings to meet the growing demand.